Healthcare / Drug Manufacturers - GeneralNasdaqGS
$330.08
-6.71 (-1.99%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 22% · confianza 25%
FCF escenarios
weak_data · normalized FCF $8.1B · quality 54.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
8/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$178.1B
P/E
23.0x
↑EV/EBITDA
13.3x
↑ROE
89.1%
↑Gross Margin
67.2%
↑Debt/Equity
6.31
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2007–2025 · 18 años de histórico normalizado
Revenue CAGR
+5.2%
FCF CAGR
+3.8%
FCF margin
22.0%
FCF / Net income
1.05x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $36.75B · net income $7.71B · FCF $8.10B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||||
| Revenue | $36.75B | $36.75B | $33.42B | $28.19B | $26.32B | $25.98B | $25.42B | $23.36B | $23.75B | $22.85B | $22.99B | $21.66B | $20.06B | $18.68B | $17.27B | $15.58B | $15.05B | $14.64B | $15.00B | $14.77B |
| Net Income | $7.71B | $7.71B | $4.09B | $6.72B | $6.55B | $5.89B | $7.26B | $7.84B | $8.39B | $1.98B | $7.72B | $6.94B | $5.16B | $5.08B | $4.34B | $3.68B | $4.63B | $4.61B | $4.05B | $3.08B |
| EBITDA | $16.90B | $16.90B | $13.36B | $14.80B | $12.17B | $11.04B | $12.74B | $11.88B | $12.21B | $11.93B | $11.90B | $10.58B | $8.28B | $7.15B | $6.67B | $5.37B | $6.56B | $6.55B | $6.29B | $5.18B |
| EPS | 14.23 | 14.23 | 7.56 | 12.49 | 12.11 | 10.28 | 12.31 | 12.88 | 12.62 | 2.69 | 10.24 | 9.06 | 6.70 | 6.64 | 5.52 | 4.04 | 4.79 | 4.51 | 3.77 | 2.74 |
| Gross Margin | 67.2% | 67.2% | 61.5% | 70.0% | 75.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | 24.7% | 24.7% | 21.7% | 28.0% | 36.3% | 29.4% | 35.9% | 41.4% | 43.2% | 43.6% | 42.6% | 39.1% | 30.9% | 31.4% | 32.3% | 27.7% | 36.8% | 37.6% | 34.8% | 26.9% |
| Net Margin | 21.0% | 21.0% | 12.2% | 23.8% | 24.9% | 22.7% | 28.6% | 33.6% | 35.3% | 8.7% | 33.6% | 32.0% | 25.7% | 27.2% | 25.2% | 23.6% | 30.7% | 31.5% | 27.0% | 20.8% |
| Balance Sheet | ||||||||||||||||||||
| Debt/Equity | 6.31 | 6.31 | 10.23 | 10.37 | 10.64 | 4.96 | 3.50 | 2.79 | 2.36 | 1.35 | 1.01 | 1.04 | 1.17 | 1.34 | 1.39 | 1.13 | 0.45 | 0.47 | — | — |
| Current Ratio | 1.26 | 1.26 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||||
| Free Cash Flow | $8.10B | $8.10B | $10.39B | $7.36B | $8.79B | $8.38B | $9.89B | $8.53B | $10.56B | $10.51B | $9.62B | $9.14B | $8.23B | $5.60B | $5.19B | $4.55B | $5.21B | $5.81B | $5.32B | $4.13B |
| Returns | ||||||||||||||||||||
| ROE | 89.1% | 89.1% | 69.6% | 107.8% | 179.0% | 88.0% | 77.2% | 81.1% | 67.2% | 7.8% | 25.8% | 24.7% | 20.0% | 23.0% | 22.8% | 19.4% | 19.3% | 20.3% | 19.4% | 16.6% |
| Valuation | ||||||||||||||||||||
| P/E | 22.95 | 22.95 | 34.55 | 24.26 | 22.73 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | 13.28 | 13.28 | 14.18 | 14.64 | 14.81 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 20.66 | 20.66 | 24.05 | 26.16 | 40.67 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||||
| Revenue Growth | 10.0% | 10.0% | 18.6% | 7.1% | — | 2.2% | 8.8% | -1.6% | 3.9% | -0.6% | 6.1% | 8.0% | 7.4% | 8.2% | 10.8% | 3.5% | 2.8% | -2.4% | 1.6% | — |
| EPS Growth | 88.2% | 88.2% | -39.5% | 3.1% | — | -16.5% | -4.4% | 2.1% | 369.1% | -73.7% | 13.0% | 35.2% | 0.9% | 20.3% | 36.6% | -15.7% | 6.2% | 19.6% | 37.6% | — |
| Dividend Yield | 3.0% | 3.0% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
27.2%
EPS terminal req.
$29.29
Spread vs growth
61.0%
5Y implied EPS CAGR
20.0%
EPS terminal req.
$35.44
Spread vs growth
68.2%
10Y implied EPS CAGR
14.9%
EPS terminal req.
$57.08
Spread vs growth
73.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+17.5%
Start / end P/E
38.1x → 23.2x
EPS bridge
7.56 → 14.23
Residual
-34.5%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.